To fill African man­u­fac­tur­ing void, BioN­Tech will pig­gy­back off plans for malar­ia mR­NA vac­cine with new man­u­fac­tur­ing sites

The lack of drug man­u­fac­tur­ing in Africa has led to a need for Covid-19 vac­cines, and the lack of a malar­ia vac­cine has led to the deaths of thou­sands of chil­dren each year. BioN­Tech will now to try and take down two birds with one stone.

BioN­Tech is ex­plor­ing pos­si­bil­i­ties to set up mR­NA man­u­fac­tur­ing fa­cil­i­ties through­out the con­ti­nent, ei­ther by part­ner­ing with oth­er com­pa­nies or through its own vo­li­tion, the com­pa­ny an­nounced in a press re­lease. These fa­cil­i­ties would have mR­NA man­u­fac­tur­ing ca­pa­bil­i­ties, and will share space with tech­nol­o­gy trans­fer hubs that are un­der de­vel­op­ment by the World Health Or­ga­ni­za­tion that line up with the strat­e­gy cre­at­ed by the Africa CDC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER